Introduction {#s0005}
============

This chapter focuses mainly on the neurologic complications associated with human infections with influenza. Where applicable, experimental animal and *in vivo* studies are presented. A brief review of molecular aspects of influenza viruses and how they replicate in respiratory and non-respiratory tissues is followed by a review of the major neurologic syndromes associated with influenza. The syndromes are presented in a historic fashion as the types of neurologic complications have varied in the 20th and 21st centuries.

Influenza virus {#s0010}
===============

Influenza viruses are members of the Orthomyxoviridae family, and are so named from the Greek *orthos*, meaning "straight" and *myxa*, meaning "mucus." The Orthomyoviridae family is composed of five genera: *Influenzavirus A, Influenzavirus B, Influenzavirus C, Thogotovirus*, and *Isavirus* ([@bb0335]). The genome of these viruses consists of 7--8 segments of negative-sense single-stranded RNA contained within enveloped virus particles (virions) that are either spherical or filamentous in morphology ([@bb0740]). The influenza viruses within this genera are categorized as A, B, or C, and differ in host range and severity of disease. Influenza types B and C primarily infect humans; however the severity of illness is relatively mild compared to influenza A viruses. Because influenza B and C remain predominantly within the human population, and neither exchanges genetic material between other influenza types, nor recombines genome segments naturally with viruses from other host species, influenza types B and C do not cause pandemics. In contrast, influenza A viruses infect a wide variety of mammals (including humans, horses, pigs, ferrets, cats, and dogs) as well as avian species. The ability of influenza A viruses to infect such a wide variety of host species that frequently come into close contact with one another permits the occurrence of co-infections with multiple influenza A viruses in permissive hosts that can serve as "mixing vessels." These scenarios can result in the creation of genetic reassortant viruses that express novel antigenic properties, which can cause periodic epidemics in immunologically naïve populations. In some cases these epidemics can spread rapidly and widely enough to be classified as a pandemic. The recent 2009 H1N1 pandemic illustrates the emergence of a highly infectious reassortant strain which resulted when a previous triple reassortment of bird, pig, and human flu viruses further combined with a Eurasian pig flu virus ([@bb1280]) and rapidly spread across multiple continents.

Influenza A viruses are further divided into subtypes based on the antigenic nature of two important spike glycoproteins found in the host-derived lipid membrane which forms the virus envelope. The hemagglutinin (HA) and neuraminidase (NA) glycoproteins project from the lipid envelope, along with the M2 protein. Influenza A virus subtypes are identified by the serotype of HA and NA expressed on the surface of the virion. There are 16 influenza virus HA types and nine NA subtypes ([@bb0340]). The HA molecule is involved in the attachment of the virus by binding neuraminic acids (also known as sialic acids) on the surface of host cells. The tropism of influenza A viruses that replicate in different species is at least partially explained by the preferential binding of certain HA molecules with sialic acids with specific linkages found in the penultimate galactose sugar of the sialic acid found on the cell surface. HA from human viruses selectively binds sialic acid residues with an α2,6 linkage, while HA molecules from avian viruses selectively bind sialic acid residues with an α2,3 linkage ([@bb0140]). Human tracheal epithelial cells contain a much higher ratio of α2,6-linked sialic acid residues, while the epithelium lining the gut of ducks contains mostly α2,3-linked sialic acid residues ([@bb0160], [@bb0565]).

The HA glycoprotein exists as a precursor molecule (HA0) that relies on cleavage by cellular proteases in order to become biologically active (HA1 and HA2). Upon binding, influenza virus is internalized via receptor-mediated endocytosis, and the resultant acidification of the endosome induces a conformational change in the HA molecule that triggers fusion of the viral and endosomal membranes, releasing the contents of the virion into the cytoplasm ([@bb0670], [@bb0710]). This proteolytic activation of HA is essential for viral infectivity and dissemination, and is critical for virus pathogenicity ([@bb1365]). In many influenza viruses and low pathogenic avian influenza viruses (LPAIV), the cleavage site in the HA0 molecule contains a single basic reside that is cleaved by trypsin-like enzymes found in the respiratory tract and limited organs, resulting in mild or asymptomatic infection. One of the virulence factors distinguishing highly pathogenic avian influenza viruses (HPAIV) from LPAIV is the presence of multiple basic amino acids present at the cleavage site, which allows for cleavage of the HA0 molecule by ubiquitous intracellular proteases. The increased cleavability of the HA molecules of HPAIV in multiple tissue types results in systemic infection in avian species ([@bb1180], [@bb0490]). These studies suggest that the ability to cleave HA is a determinant of the tissue tropism for avian influenza viruses and the differences in tissue tropism can determine the severity of disease outcome. It has been suggested that the HA molecule may play a role in neurovirulence in mammals ([@bb0890]), supported by studies in which a multibasic cleavage site has been cloned into low pathogenic viruses, and increasing virulence ([@bb0905]). The acquisition of natural forms of more cleavable HA may occur through polymerase slippage, mutations, reassortant events with coinfections, or non-homologous recombination events.

Given the role of the HA molecule in the attachment of virus to host cells and potential for increased virulence, the blockade of this interaction by host-derived neutralizing antibodies is considered the gold standard by which influenza vaccine efficacy is currently evaluated.

The NA glycoprotein serves to cleave sialic acid from the cell surface. This function is critical in the release of budding viruses from infected cells, as the HA contained in the lipid membrane of budding viruses is effectively anchored by cell surface sialic acid. The NA molecule cleaves the sialic acid, releasing the virus particle and allowing for virus spread. Studies involving inhibitors of NA or temperature-sensitive NA mutants have demonstrated an accumulation of aggregated virus particles on the infected cell surfaces, which are unable to be fully released ([@bb0975], [@bb0980], [@bb0970]).

Influenza viral replication {#s0015}
===========================

Influenza virus is transmitted primarily by inhalation and by direct contact inoculating the nasal mucosa, infecting epithelial cells throughout the respiratory tract. Tropism for the upper respiratory tract of human seasonal influenza viruses (subtypes H1, H2, and H3) is determined by their preference for the 2,6-galactose-linked sialic acid receptor on ciliated cells. Tropism for the lower respiratory tract among avian strains (H5 and H7 subtypes) stems from preference for binding to the 2,3-gal receptor, particularly on mucin-secreting cells, and explains in part the more common primary viral pneumonia among avian influenza infections ([@bb0835]). Both types of receptor are distributed throughout the respiratory airways, however, and the swine-origin H1N1 pandemic strains are also complicated by primary viral pneumonia more often than seasonal H1N1 viruses. Seasonal, avian, and pandemic strains exhibit different replication efficiencies in airway epithelial cells, explaining in part the different virulence and transmission phenotypes ([@bb0870]). In uncomplicated influenza infection of nasal and upper-airway epithelial cells results in secretion of virus, cytokine and chemokine secretion, influx of neutrophils, and desquamation of apoptotic cells into the airways ([@bb1250]). Symptoms are due to both the cytolytic viral infection and the cytokine response, suggested by the coincidence on day 2 of peak viral secretion, peak symptoms, and peak interleukin-6 (IL-6) and interferon-alpha (IFN-α) secretion in volunteers ([@bb0470]). Death is usually due to severe pulmonary infection as acute respiratory distress syndrome or primary viral pneumonia. In primary influenza pneumonia the virus replicates preferentially in ciliated airway epithelial cells, alveolar macrophages, and type I pneumocytes, although replication can occur in type II pneumocytes and non-ciliated epithelial cells ([@bb0685]).

While seasonal strains replicate almost exclusively in the respiratory tract, swine-origin pandemic strains replicate in some extrapulmonary tissues; avian strain distribution is discussed below. How the virus reaches extrapulmonary tissues is not clear. Viremia has been documented by culture in some studies but a review concludes that viremia is rare and occurs in a narrow window of time ([@bb0750]). The sialic acid-decorated glycolipids and glycoproteins that serve as receptors for the HA protein are ubiquitous on the surface of most mammalian cells, providing opportunity for infection, but positive demonstration of infection is rare ([@bb0685]). Because positive culture could arise from blood contamination, *in situ* hybridization and immunohistochemical demonstration of viral antigen in tissue cells are required to prove viral replication and such demonstrations in brain and heart are limited ([@bb0685]).

General principles of the immune response to influenza virus {#s0020}
============================================================

Recovery from primary influenza infection resides in the innate immune response and the development of an adaptive antibody response, particularly in the IgM fraction ([@bb1005]). Although timely diagnosis is usually made by virologic assays, retrospective diagnosis is reliable by serum hemagglutination inhibition antibody specific to the infecting strain appearing 5--10 days after infection. Recovery from a repeated infection with the same or cross-reacting subtype of influenza virus is vested primarily in the CD8 + T-cell memory response. Influenza-specific T cells accumulate in infected lung foci in animal models. The presence of viral antigen directly stimulates the expansion of the influenza-specific T- and B-cell populations, and clearance of the antigen is associated with the disappearance of activated T and B cells in tissue and blood.

Pathogenesis of influenza infections {#s0025}
====================================

Since viruses have coevolved with their hosts, influenza virus stimulates a complex array of innate immune responses in the infected cell and the virus counteracts these responses with multiple virulence factors, primarily the viral NS1 protein, targeting specific pathways in the innate response ([@bb0440]). Pathogenicity, defined as tissue injury and illness, originates from two interrelated features of the infection, the viral replication itself inducing epithelial cell death through the apoptosis program ([@bb0780]) and the subsequent host response with cytokine-driven mucosal and systemic inflammation. For example, the recently described viral protein PB1-F2 is proapoptotic, and the NS1 protein has been shown to have both proapoptotic and antiapoptotic activities. NS1 proteins from different strains antagonize type 1 IFN-α/β with different levels of efficiency, yet type 1 IFNs are also primary inducers of apoptosis. Thus the final consequence of these complex, often opposing, activities in regulating viral replication remains controversial.

Animal models provide some insights into the pathogenesis of influenza ([@bb0050]). Epizootic strains infect swine, horses, dogs, cats, domestic poultry, and water birds, but only the avians often exhibit neurovirulent behavior. However, the mouse, ferret, guinea pig, and non-human primate have provided the most insight into pathogenesis. Animal models demonstrate that pulmonary inflammation is a direct consequence of infection of bronchial and bronchiolar epithelial cells, alveolar pneumocytes, and alveolar macrophages. Breakdown of the alveolar barrier function of the pneumocytes leads to alveolar flooding, influx of neutrophils and histiocytes, and plugging of small airways with desquamated cells. Nitric oxide and oxygen radicals play a significant role in pulmonary injury in a murine model of H2N2 infection ([@bb0010]).

In contrast, the contribution of viral replication in brain tissues remains unclear. Mouse microglia and astrocytes can be infected *in vitro* by both H1N1 and H5N1 subtypes and secrete proinflammatory proteins IL-1β, IL-6, and tumor necrosis factor-alpha (TNF-α), with greater induction by H5N1 infection ([@bb1350]). However, a porcine H1N1 virus adapted to a lethal strain for mice did not replicate in any neural or other extrapulmonary tissues ([@bb0395]). In the murine model of the neurovirulent WSN strain (evolved from the pandemic 1918 strain), it was not clear whether the encephalitis was a result of direct virus-induced apoptosis or was mediated by immunologic or inflammatory responses ([@bb0895]). In this model selected brainstem neurons are targeted after injection of virus into the olfactory bulb, and local defense is mediated by activated glial cells and apoptosis of infected neurons ([@bb0880]). In the ferret model, the brain is invaded from the olfactory sensory cells in the nasal turbinates through the cribiform plate to the olfactory bulbs and thence to the basal ganglia ([@bb1145]).

Whether cytokines are antiviral, perpetrators of cellular injury, or merely correlates of disease severity is unclear. The cytokines IFN-β and TNF-α have both antiviral and proinflammatory activity. Dysregulation of inflammation induced by the virus is associated with a lethal outcome but depends on the animal model. For example, in mice a lethal HPAI H5N1 strain was more pathogenic, including brain invasion, than the pandemic 1918 strain, and multiorgan dissemination correlated with early and sustained induction of inflammatory genes with active inhibition of the lipoxin-mediated anti-inflammatory response. In contrast, in the non-human primate, the 1918 strain was more pathogenic with early upregulation of cell death genes, inflammasome genes and IL-1β, whereas the H5N1 strain downregulated these genes. It must be kept in mind that viral replication rate with direct cytolytic injury also determine the clinical outcome and immunopathology in murine H5N1 infection ([@bb0465]). Thus, the role of multiple determinants of pathogenesis remains complex, but the relationship between proinflammatory, cerebral metabolism, and regional brain function may offer future insights into encephalopathy ([@bb1115]).

Pathogenesis of human influenza-associated encephalopathy is hampered of course by the lack of tissue studied during the acute infection, but numerous studies are beginning to suggest the role of systemic inflammation. Seasonal influenza-associated neurologic complications in humans are generally categorized into diagnostic groups, and may represent overlapping pathogenesis and disease severity. These groups include febrile seizures, encephalopathy, encephalitis, Reye\'s-like syndrome, acute disseminated encephalomyelitis, and acute necrotizing encephalitis (ANE). Details of these types of complications in humans appear later.

In summary, there is a clear hierarchy of influenza A subtypes in the continuum of pathogenesis severity in the lung and likely the brain as well, ordered as follows: seasonal H1N1 \< seasonal H3N2 \< pandemic 2009 H1N1 \< sporadic H5N1 ≤ pandemic 1918. In head-to-head comparison studies, this hierarchy has been demonstrated for viral replication in human and ferret epithelial cells ([@bb0870]), in disease severity in mice ([@bb0620], [@bb0395]), in ferret influenza pneumonia ([@bb1305]), and in lung pathology in animal models and human cases ([@bb0430]).

Neurologic syndromes associated with standard human influenza A and B virus {#s0030}
===========================================================================

1918 influenza H1N1 pandemic {#s0035}
----------------------------

The influenza pandemic of 1918--1919 dramatically changed how the world thought about influenza. The previous major pandemic occurred in 1889--1890 and introduced the first important epidemiologic studies through the work of Otto [@bb0730]. Viruses were unknown. The beginnings of virology started in the 1890 s with the study of tobacco mosaic virus. Lessons learned from the 1889 pandemic were that it was communicable and never rose spontaneously. The disease was respiratory and had an explosive onset, with pneumonia as the most serious complication. Most cases occurred in winter and spring months. Deaths in 1889 were uncommon and mainly in the elderly. The influenza pandemic could spread around the world but did not travel faster than humans could travel.

Twenty-eight years later an outbreak of influenza arose in the spring in Spain. However, there is now evidence that the original viral strain likely occurred in another country and spread early to Spain ([@bb1245]). The first wave was relatively benign but a second wave occurring in the fall and winter was much more virulent and rapidly spread around the world, causing many deaths. The third wave occurred in early 1919 and was variable in severity. It is estimated that about one-third of the world\'s population of 500 million was clinically infected during the pandemic ([@bb0080]). The worldwide total number of deaths was estimated to be 40 million ([@bb0995]). In the United States, there were approximately 675 000 deaths ([@bb1295]) ([Fig. 30.1](#f0005){ref-type="fig"} ). The estimated mortality rate was at least 2.5%, compared with less than 0.1% reported in subsequent influenza epidemics ([@bb0815]).Fig. 30.1Military personnel hospitalized in makeshift hospital during an outbreak of influenza A 1918 at Camp Funston, Kansas.(Courtesy of Armed Forces Institute of Pathology library.)

The majority of individuals who died were previously healthy young adults between the ages of 15 and 44 years ([@bb0760]). In this age group, the influenza death rate was 20 times higher than seen in other influenza epidemics ([@bb1155]) and not seen in the 1889--1890 pandemic ([@bb0320]). The explanation for the high death rate in these healthy adults remains unexplained. It should be noted that, when deaths are calculated on an age-specific death rate per 100 000, infants less than 1 year and those over 75 years also had elevated mortality rates.

The 1918 pandemic occurred before influenza virus was recognized. It was not until 1930 when the first human and swine influenza viruses were isolated ([@bb1150]) and Smith et al. reported the isolation of human influenza in viruses in ferrets in [@bb1165]. However, using modern polymerase chain reaction (PCR) techniques, Taubenberger and others have now sequenced the entire virus using frozen and formalin-fixed lung tissue of patients who died during the pandemic ([@bb1255], [@bb1245]). The virus sequencing and analyses of antibody titers of 1918 influenza survivors ([@bb1010], [@bb0275]) demonstrated that the virus was a novel H1N1 virus. Reassortment involving genes encoding surface proteins (HA and NA) appeared critical for the production of a pandemic virus allowing the new virus strain to spread and replicate efficiently in humans ([@bb1245]). Current evidence suggests that the prior circulating influenza virus had an H3 subtype ([@bb0275]) and that likely both the NA and HA viral proteins were new. However, neither the 1918 HA nor the 1918 NA genes have obvious genetic features that can be directly related to virulence ([@bb1245]). Recent interest has focused on the novel non-structural protein NS1. The NS1 protein is effective in blocking type 1 IFN and may have allowed the 1918 influenza to replicate rapidly and spread quickly throughout the upper and lower respiratory tract ([@bb1230], [@bb1345]).

The majority of deaths were pulmonary and many patients succumbed to secondary bacterial pneumonia since antibiotics were not available in 1918 ([@bb0720], [@bb1385], [@bb1380]). However, others died within a few days of the onset of respiratory symptoms from either massive pulmonary edema or acute pulmonary hemorrhage ([@bb0720], [@bb1385]). At death, there was remarkably little other organ pathology, including the brain ([@bb1250]).

Although the deaths have been mainly attributed to respiratory causes, this pandemic has been associated with a number of unique neurologic illnesses that are discussed below.

### Encephalitis lethargica {#s0040}

Encephalitis lethargica (EL), von Economo\'s encephalitis, epidemic encephalitis, or brainstem encephalitis is covered in detail in Chapter 36. The etiology of EL is unknown but it has a controversial association with the 1918 influenza pandemic. It is clear that an epidemic of what is now usually termed brainstem encephalitis did develop mainly from 1918 through about 1924. Sporadic cases of brainstem encephalitis were reported by von Economo in a Viennese clinic in 1917 and 1918 ([@bb1320], [@bb1325]). Similar cases were soon reported around the world with the peaks during 1919 and 1920.

Many of the reported cases had signs and symptoms typical of brainstem encephalitis. Prodromal signs and symptoms often included lethargy, insomnia, sleep reversal, headache, vomiting, vertigo, dry mouth, hiccups, dysuria, tremors, and diplopia and lasted 3--21 days. A mild to moderate fever was common. Some patients never progressed. In general, two forms of EL were subsequently described. Until about 1920, a somnolent-ophthalmoplegic form was the most common. Patients developed progressive somnolence until they became stuporous or comatose ([@bb1320]). The face was characteristically impassive and mask-like. The somnolence lasted 1--2 weeks and gradually diminished or progressed to coma ([@bb1030]). Patients when somnolent were noted to have ocular abnormalities that ranged from ophthalmoplegia to ptosis, diplopia, and pupillary irregularities. Facial palsy, hemiparesis, and cerebellar ataxia could develop. The death rate was higher in the somnolent-ophthalmoplegic form and ranged up to 50%, but severe neurologic sequelae were uncommon in survivors.

In the years from 1920 to 1924, a hyperkinetic form was recognized with restlessness, tics, myoclonus, chorea, disturbances of intraocular muscles, and frenetic psychiatric disturbances ([@bb1030]). This form had a more rapid onset and often was accompanied by limb weakness, insomnia, and sleep reversal. The hyperkinetic form could also progress to the somnolent form. Other clinical pictures of what was called EL were reported. The mortality rate of the hyperkinetic form was up to 40% but neurologic sequelae were more common than in the somnolent form ([@bb1030]).

In the first years of EL, most of the cases were reported in the winter months (November to March) ([@bb0170]). In later years more cases were reported in summer months. The majority of patients were from 10 to 40 years and the gender ratio was about equal.

Lumbar punctures were occasionally performed during the acute phase. Opening pressure, when recorded, was elevated ([@bb1320]). A mild lymphocytic pleocytosis was not infrequent, with cells seldom exceeding 30/mm^3^. There was often a slight increase in total protein but the glucose level was normal. In rare cases the cerebrospinal fluid (CSF) was highly suggestive of bacterial meningitis.

[@bb0085] in Iowa reported a 37-year-old man who in January 1919 developed influenza with secondary pneumonia and recovered. In March he developed the somnolent form of EL and died 2 weeks later. His brain showed brainstem encephalitis and vascular congestion. [@bb0030] reviewed 112 brain autopsies of EL. They found the median age to be 29 years, with the majority occurring between 10 and 40 years. The median duration of the illness was 10 days but the majority were less than 5 days. The neuropathology usually demonstrated inflammation in the brainstem ranging from the midbrain to the medulla. There was lymphocytic perivascular cuffing, foci of parenchymal lymphocytes, foci of glial nodules, and vascular congestion. The third-nerve nucleus showed focal pathology in half the patients along with midbrain pathology but the substantia nigra had lesions in only 12%. In the cerebral cortex, vascular congestion, cerebral edema, glial cell proliferation, foci of inflammation, and focal hemorrhages were often seen. Thirty-six percent of patients exhibited pathology in the basal ganglia characterized by infiltration of mononuclear cells and congestion. The meninges had vascular congestion but seldom white-cell infiltration. Thus, most patients who died demonstrated evidence of inflammation in the brainstem and occasionally in the cortex plus vascular congestion with evidence of increased intracranial pressure.

There continues to be considerable controversy regarding the role the 1918 influenza virus played in causing EL. The underlying problems include the lack of a clear, clean definition of EL. The term encephalitis was poorly defined in that era and the many arboviruses and other viruses that are now recognized to cause encephalitis were not known. In addition, many physicians during this period were untrained in neurologic diseases and how to perform a careful neurologic exam. As such, many of the clinical descriptions of EL are vague. This wide variation in clinical features suggests that several different etiologies of illnesses were lumped together as EL.

In spite of these problems, there is evidence both clinically and neuropathologically that a unique form of brainstem encephalitis did develop and peaked during the 1918 influenza pandemic and slowly disappeared by the end of the 1920s. What is less clear is when it first appeared and disappeared and how many cases actually occurred. Sporadic reports of "encephalitis" appear as early as 1915 and continue well into the late 1920s but without obvious clustering.

von Economo is credited with the first comprehensive description based on cases he saw in 1916 in Vienna ([@bb1320]). However, many countries, including the United Kingdom and the United States, were describing similar cases in the fall of 1918 and in 1919. Reports from New York City noted the cases paralleled the 1918 influenza pandemic. The most careful study came from a review of cases reported in Seattle, Washington, and in Samoa ([@bb1025]). The authors identified 142 EL deaths as well as deaths related to influenza/pneumonia during 1918 through 1926. There was an association with the 1918 influenza but the EL cases clustered about 12 months after each of three waves. The hospital death records of the EL cases did not mention whether the individuals had experienced infection from the 1918 influenza months earlier. The authors also reviewed death records from both Western Samoa and American Samoa. In Western Samoa, the 1918 influenza hit the island in November 1918 and cases of EL appeared over the next few years and disappeared. However, American Samoa had a quarantine and developed no cases of influenza or EL. Finally, the authors presented reported cases of EL from Sweden and Switzerland that clearly demonstrated high peaks of EL that correspond to late 1919 or 1920 and followed shortly after their peaks of influenza.

All reports of EL note that the disease is not transmissible to others, consistent with EL being a consequence of another illness such as influenza or an infection that required a vector. Attempts to pass EL brains into many experimental animals failed and pathologic studies failed to identify any obvious bacteria, parasites, or specific types of inclusion bodies. The peak number of cases almost always occurred in the winter and not in the summer, when arboviruses could be a cause. The peak age distribution of 864 cases of EL was 10--50 years in previously healthy adults and matches closely the attack rate of the 1918 strain of influenza ([@bb0825]).

There are many arguments against the association of EL with the 1918 influenza virus. EL-like illness has not been associated with other human strains of influenza virus. Experimental with strains of human influenza virus, pathology identical to EL has not been seen in experimental animals. However, some of the highly pathogenic avian influenza strains demonstrate somewhat similar brain pathology in animals (see end of chapter). The unusually long delay of 6 months or more for the appearance of EL after the 1918 influenza hit a city is difficult to explain. Many reports of acute EL patients did not report that the patients previously experienced influenza. However, the lack of a clear association of EL with a prior influenza infection may be due to the fact that patients rarely sought medical attention for influenza and may not have suffered a severe case of influenza. Nevertheless, there is considerable evidence that EL never developed in patients during their acute influenza infection. Finally, [@bb0840] failed to detect influenza RNA in archival brain tissues from acute EL.

In summary, clusters of EL appeared around the world about the same time as the 1918 influenza pandemic and disappeared as the 1918 virus pandemic waned and disappeared. Subsequently, only rare cases of brainstem encephalitis have developed and most have been proven due to non-influenza viruses. It is unlikely that EL occurred as a direct complication in a patient with the 1918 influenza. However, a postinfectious influenza complication has not been ruled out. If EL was not due to the 1918 influenza virus, then the etiology must have been an agent closely associated with the 1918 influenza as it spread around the world beginning and disappearing about the same time.

Postencephalitic parkinsonism (PEP) {#s0045}
-----------------------------------

A large cluster of young adults developed parkinsonism from 1918 into the 1930s that were associated with previously having EL. It was recognized that these postencephalitic patients had many features of typical Parkinson\'s disease but differed in several aspects. First, they were much younger at the age of onset. In a series by [@bb0280] from New York City, the mean age of onset of 31 patients who had a reliable history of EL was 29 years, compared to 57 years for cases of classical Parkinson\'s disease. Similarly, [@bb0270] reviewed 320 cases of parkinsonism diagnosed in the United Kingdom from 1900 to 1942. Of the 100 cases from 1920 to 1930, two-thirds appeared to follow EL. The modal age of onset was in the third decade. The PEP cases could immediately follow EL or develop up to 19 years later but most sought medical attention within 2 years of EL. In both series, atypical features for Parkinson\'s disease were common and included oculogyric crises, ocular nerve abnormalities (abnormal external ocular movement, pupillary irregularities, poor accommodation), excessive salivation, and marked somnolence. Some patients also had hemiparesis, dystonia, chorea, tics, bulbar palsies, and behavioral disturbances.

Various series have estimated that, of survivors of EL, one-third developed PEP by 3 years and one-half after 5 years ([@bb0280]). One epidemiologic study even argued that all Parkinson\'s disease could be attributed to a cohort that developed the illness around 1920 ([@bb1015]). However, Parkinson\'s disease had been recognized long before 1920. Charcot noted that Parkinson\'s disease was the fifth most common disease treated at the Salpetrière and the disease was well recognized in New York City when studied from 1888 to 1904 ([@bb0460]).

The neuropathology of PEP has generally shown features consistent to EL but with marked degeneration of the substantia nigra. [@bb0845] reported a 51-year-old Minnesota farmer who developed EL in 1920 and survived with improvement over 2 years. He continued to have increased somnolence but then developed a pill-rolling tremor, masked facies, bradykinesia, and rigidity consistent with Parkinson\'s disease. He died several months later. His brain showed persistence or residuals of a brainstem encephalitis with some perivascular cuffing of lymphocytes in the midbrain and elsewhere. There was marked loss of substantia nigra neurons and early gliosis. Other reported cases found similar pathology with persistent inflammation of lymphocytes and plasma cells around blood vessels months to years after the EL subsided, widespread distribution of lesions throughout the brain but mainly the brainstem, profound degeneration on neurons in the substantia nigra, and degeneration of neurons also in the striatum, pallidum, cortex, and midbrain tegmentum ([@bb0295]).

There have been several attempts to identify or isolate influenza virus from the brains of PEP patients. Influenza virus antigen was identified in the midbrain and hypothalamus of frozen sections by immunofluorescence using fluorescein-conjugated globulin directed against several strains of influenza A (H1N1) virus ([@bb0375]). However, others have questioned this study and similar immunofluorescent studies have been negative ([@bb0295]). No evidence of influenza RNA was detected using PCR studies of formalin-fixed tissues ([@bb0840]). Similarly, no differences were found in antibody distribution or titers to several influenza A (H1N1) strains between PEP patients and matched controls ([@bb0830], [@bb0300]).

Subsequently rare cases of parkinsonism have been reported in patients with viral encephalitis due to arboviruses (Japanese B, West Nile, and St. Louis) and coxsackievirus ([@bb1340], [@bb1020], [@bb1050]). In many of these cases, the parkinsonism was transient and resolved.

In summary, there is considerable evidence that PEP could develop rapidly or later as sequelae of EL. PEP developed in a much younger age than classical Parkinson\'s disease, began during the period when the 1918 strain of H1N1 influenza was pandemic, and has not reappeared since that cohort. However, there is no evidence for persistence of influenza virus in the brains of these patients. If EL was a sequela of the pandemic virus, then PEP was likely also. Although the Spanish 1918 influenza H1N1 strain has now been sequenced, it has not been assembled into an infectious virion. As such, the full biology of the virus remains incomplete. To date, however, there is no evidence that the 1918 strain during the pandemic directly infected and replicated in the brain of patients.

Reye\'s syndrome {#s0050}
----------------

In 1963 Reye and others described both the clinical and pathologic features of 21 children who died with a severe encephalopathy and fatty degeneration of the liver. [@bb0590] reported an association with what was soon called Reye\'s syndrome (RS) and influenza B viral infections. Although occasional patients were reported earlier who in retrospect may have had RS, after 1963 cases were soon recognized around the world ([@bb1300], [@bb0415], [@bb0285], [@bb0945]).

By the 1970s, RS had become the most common hepatic cause of death in children and the second most common cause of death among virus-related diseases of the central nervous system (CNS) in children ([@bb1055]). During the peak years of the 1970s, RS was commonly occurring worldwide. In the United States, the attack rate ranged from 30 to 60 cases per 100 000 influenza B infections ([@bb0155]) and RS occurred from 0.3 to 0.4 cases per 100 000 influenza A infections. The influenza A infection could be associated with either the A H3N2 or H1N1 strain. Temporal and geographic associations between influenza B and RS outbreaks were repeatedly described ([@bb0590], [@bb0410], [@bb1045], [@bb0765], [@bb0145], [@bb0925]).

The clinical features of RS are fairly characteristic ([@bb0200]). The syndrome developed primarily in children with the peak between the ages of 5 and 14 years ([@bb1055]). However, histologically confirmed cases have occurred in neonates and adults ([@bb0525], [@bb0185]). The clinical manifestations can be broadly divided into a prodrome and RS. The most commonly used staging system has been based on the system of [@bb0775]. Individuals can progress relentlessly from stage I through stage V or stop at any stage and recover. The factors that govern progression of the disease through the stages are unknown.

A prodrome has been reported in over 90% of well-studied cases. In all, 60--87% of cases have been associated with an upper respiratory disease, 20--30% have been associated with chickenpox, and 5--15% with diarrhea ([@bb0145]). The large majority of cases have been associated with preceding infections of either influenza B or A viruses ([@bb1200]). A variety of other viruses have had one or a few cases of RS ([@bb0200]).

Vomiting is the cardinal feature of stage I. The vomiting is abrupt in onset and is repetitive, lasting hours to several days. The patient is lethargic and irritable. Fever may be present but jaundice is not. Individuals have normal strength, sensation, cranial nerves, and reflexes. Many patients in stage I do not progress further and recover ([@bb0480]). In stage II the child is stuporous, may have a non-purposeful response to pain, show sluggish pupillary reactions, and demonstrate conjugate eye deviation to the oculovestibular reflex. In stage III the patient is comatose and shows decorticate posturing to pain. In stage IV the posturing is decerebrate, breathing is disorganized, and the oculovestibular reflex may be absent. In stage V, the patient is deeply comatose without spontaneous respirations, muscle tone is flaccid without posturing, and pupillary reflexes are absent. Few patients in stage V survive.

There is no single diagnostic laboratory test for RS. Arterial blood ammonia concentrations are usually at least threefold elevated and may exceed 1000 μg/dL ([@bb0530], [@bb0450]). Other biochemical changes involving the liver are always present. Serum transaminases (alanine transaminase and aspartate transaminase) are typically elevated 20-fold above normal. Prothrombin times are often prolonged but hemorrhages are rare. A variety of other serum abnormalities may be present ([@bb0200]).

The CSF may have a normal opening pressure early in the illness but soon becomes highly elevated ([@bb0860]). The CSF is acellular and has normal glucose and protein levels. The electroencephalogram (EEG) is always abnormal, showing slowing of background activity, seizures, burst suppression activity, and electrocerebral silence in stage V ([@bb0035]). Neuroimaging is often normal in the early stages but in later stages demonstrates diffuse cerebral edema and possibly brain herniation ([@bb1080]).

The differential diagnosis of a Reye\'s-like syndrome in the absence of an outbreak of influenza A or B or chickenpox is long and includes acute generalized diseases, toxins, drugs, and genetic diseases ([@bb0200]). The diagnosis of RS is epidemiologically defined by the Centers for Disease Control and Prevention (CDC) as an acute, non-inflammatory encephalopathy documented by the clinical picture of alterations in the level of consciousness and liver dysfunction ([@bb1055]).

The dominant brain pathology in RS is moderate to severe brain swelling due to cerebral cytotoxic edema rather than vasogenic edema ([@bb1040], [@bb0325], [@bb0185]). In severe cases, widespread cortical neuronal degeneration and large myelin blebs occur. Inflammation is absent and viral particles or inclusion bodies are not seen. The liver in all stages is slightly swollen and increased in weight for the age of the patient. Liver biopsies show several characteristic changes. On frozen histologic sections, lipid is abundant and uniformly distributed. Hepatocyte cytoplasm is distended by microvesicular fat droplets ([@bb1110], [@bb1205]). On paraffin-embedded sections stained with hemotoxylin and eosin, there is little cytoplasmic vacuolation early but later there is a uniform foaminess of the cytoplasm. Inflammation is rare. By electron microscopy, hepatocytes show microvesicular fat droplets and prominent morphologic changes in mitochondria ([@bb0985], [@bb0055]). The mitochondria often measured 2--3 μm in diameter with the outer membrane deformed by deep cytoplasmic invaginations and normal-appearing cristae. Liver biopsies obtained weeks to months after recovery appear almost normal. The kidney may also demonstrate lipid droplets within the cytoplasm of cells of the loop of Henle and proximal convoluted tubules. The myocardium occasionally also demonstrates lipid accumulation and abnormal mitochondria.

Management of children with RS has been primarily through attempts to control increased intracranial pressure ([@bb0150], [@bb0265]). Intracranial pressure monitors were often placed with a goal of maintaining the pressure below 20 mmHg ([@bb1060]). Hyperventilation was a common method and often continued for days. It was often successful in controlling the intracranial pressure. However, the long-term consequences of brain ischemia produced neurologic sequelae. The risk of long periods of cerebral vasoconstriction were not recognized then. Use of mannitol intravenously was beneficial for 1--2 days but the serum osmolality level needed to be kept below 320 mOsmol/L. Even removal of parts of the calvarium and hypothermia were attempted as heroic methods. Treatment of the hyperammonemia was difficult. Use of peritoneal dialysis, hemodialysis, or plasma exchange did not appear to improve survival ([@bb0150]). Vitamin K was usually administered. Anti-influenza drugs available at the time did not made a difference in outcome.

The early mortality rate in the United States was 40% but then fell to between 30 and 35% due to better intensive care and earlier detection of mild cases ([@bb1055]). In the United Kingdom, the mortality rate was 41% ([@bb0130]). In survivors, the sequelae were mainly neurologic, with over one-third having various aspects of mental retardation, hemiparesis, seizures, cortical blindness, and apraxia ([@bb0075], [@bb1125]).

The pathogenesis of RS remains a mystery. There is overwhelming evidence that outbreaks and individual infections with influenza B virus were associated with developing the syndrome. Infections with influenza A virus and varicella-zoster virus also were associated with the syndrome. In addition to the acute influenza viral infection, there is strong epidemiologic evidence that taking aspirin (acetylsalicylic acid) early in the influenza predisposed to developing RS ([@bb0510], [@bb0515]). There was no evidence that these children were given excessive amounts of aspirin as the trigger. However, the aspirin and influenza correlation with RS was not close to one to one. Many children were reported who developed RS associated with influenza but had no exposure to aspirin. Two retrospective studies found that aspirin was given to the majority of children with flu symptoms that did not develop RS (71% and 74%) ([@bb0455], [@bb1330]). Nevertheless, when warnings against children taking aspirin when developing a flu-like symptoms were widely circulated in the mid-1980s, the incidence of RS dramatically fell ([@bb1035]). By the early 1990s, RS around the world was rare.

There are several unexplained questions regarding the association of aspirin and RS. First, for aspirin alone to cause microvesicular steatosis of the liver, it requires high overdose intoxication. Second, acetylsalicylic acid was widely administered to children with fevers and flu symptoms since the early 1900s and was widely used even during the 1918, 1958, and 1964 influenza pandemics. Third, acetaminophen was marketed in 1956 and ibuprofen marketed in 1969 (just before the RS epidemic) and given to children with influenza, but neither has been associated with RS. Fourth, clear dose--response curves for aspirin have not been established for RS. The current argument is that any aspirin consumption can trigger RS in susceptible individuals. Fifth, cases of RS fell simultaneously around the world, although warnings about aspirin were publicized mainly in developed countries.

In favor of the association, there are strong epidemiologic arguments that aspirin was associated with RS if the child was also infected with influenza ([@bb0405]). Studies have demonstrated that salicylate inhibits β-oxidation of long-chain fatty acids in rodent liver mitochondria, leading to a possible explanation of why susceptible patients with RS have abnormal liver mitochondria and increased hepatic triglycerides ([@bb0235]).

Numerous attempts have been made to create a good animal model for RS. In general, animal models have focused on chemicals, infectious agents, or combinations of the two (reviewed by [@bb0260], [@bb0240]). Mouse models similar to RS have been developed in which juvenile mice given intravenous influenza B virus develop many of the clinical, laboratory, and pathologic features of RS 1--3 days later ([@bb0475], [@bb0205], [@bb0215], [@bb0190]). The mice developed elevated arterial serum ammonia, transaminase elevated levels, and hypoglycemia. The animals became lethargic, often developed seizures, and died. Microvesicular fatty degeneration was present throughout the liver with mitochondrial abnormalities seen on electron microscopy that was similar to that seen in human RS livers. The brain demonstrated cerebral edema by light and electron microscopy as well as biochemical studies. No inflammation was seen in the liver or brain but was present in the trachea. No virus was isolated in the liver or brain but virus could be isolated from the respiratory tract. However, viral antigens by immunoperoxidase staining were detected in liver hepatocytes and cerebral endothelial cells. Influenza RNA was also detected in the brain and liver. Thus the liver and brain were non-permissive influenza viral infections while the trachea infection was permissive and produced virions. The addition of aspirin to the mouse model did not increase mortality ([@bb0210]).

Young ferrets administered intranasal influenza virus and placed on an arginine-deficient diet developed severe hyperammonemia, serum transaminase elevations and an encephalopathy and fatty degeneration of the liver ([@bb0250]). Unfortunately, normal ferrets placed on an arginine-deficient diet also develop severe hyperammonemia and encephalopathy ([@bb0245]). Finally, a spontaneous Reye\'s-like disease has been recognized to occur in Balb/c by J mice in which the mice become lethargic and stuporous and die ([@bb0070]). No viruses or other infectious agents have been isolated from the mice but serologic studies have suggested an infection with a coronavirus.

Leaving the questions about the association with aspirin aside, it still remains unclear how influenza B or A can cause RS. Clinically, RS does not occur at the peak of the influenza but rather as the patient is beginning to recover. Although influenza virus can be isolated often from other tissues such as the nasopharynx or lungs, it is rare for the virus to be isolated from blood, liver, or brain by conventional techniques ([@bb0940], [@bb0695]). Liver and brain biopsies examined by electron microscopy have not identified any budding influenza virus-like particles. Unfortunately, PCR techniques and other nucleic acid technology were not available then that would have been more sensitive. There have been no subsequent reports studying stored RS tissues using these technologies. Limited clinical laboratory studies indicated that no particular strain of influenza virus caused RS. The pathologic findings in the liver and brain do not suggest viral encephalitis or hepatitis. Thus, how influenza virus may have caused RS remains a mystery. In a later section, current theories of the pathogenesis of many of the neurologic complications of influenza will be discussed.

Influenza, influenza vaccine, and Guillain--Barre syndrome {#s0055}
==========================================================

Guillain--Barré syndrome (GBS) is a transient monophasic, rapidly evolving polyradiculoneuropathy with symmetric motor weakness and variable autonomic features ([@bb1065]). Currently there is no specific diagnostic test but patients usually have flaccid limb weakness that may progress to paralysis, weakness of respiratory muscles requiring mechanical ventilation, and cranial motor nerve palsies. Initially the patient is afebrile and the CSF is acellular and otherwise normal. Delayed motor nerve conduction velocities in peripheral nerves are usually seen by electromyography beginning after 1 week. The peripheral nerve pathology shows inflammation in the nerve with lymphocytes and macrophages surrounding endoneural blood vessels and causing adjacent segmental demyelination ([@bb1065]). Acute treatment has either been plasma exchanges or intravenous pooled immunoglobulin. Both have been shown to shorten the time on a respirator and time to walk again ([@bb1065]).

The syndrome has three different clinical patterns but all are likely to have an autoimmune basis. The strongest associations with GBS have been with preceding infections of *Campylobacter jejuni* and cytomegalovirus. However, both influenza viral infections and vaccinations with both live and killed influenza viruses have been associated with GBS. Currently there is no evidence that patients with acute influenza are at risk of developing GBS during their respiratory infection. However, there are epidemiologic associations with a preceding influenza-like infection. These associations date at least to 1946 when five cases of GBS developed after an influenza-like illness ([@bb0735]). In 1959 two fatal cases of GBS were reported in patients who had serologic evidence of a recent influenza B viral infection ([@bb1375]). Fifty-two cases of GBS in the United Kingdom were serologically examined for evidence of a preceding viral infection ([@bb0855]). They reported a high incidence of upper respiratory tract infections occurring within 1 month of onset of the GBS but serologic evidence of true influenza was uncommon.

Epidemiologic studies generally have confirmed that preceding influenza-like respiratory illnesses are commonly associated with GBS but clear evidence that the respiratory illness was influenza has been lacking. An epidemiologic study of GBS in the greater Paris area from 1996 to 2001 found that 22% were associated with *C. jejuni* infections and 15% were associated with a preceding infection with cytomegalovirus ([@bb1160]). However, 60% of the GBS cases peaked in the winter and half were preceded by a vague respiratory infection, influenza-like syndrome, or gastrointestinal illness.

A second study from UK National Health Service hospitals reporting cases of GBS from 1993 to 2002 found an association between the numbers of reports of laboratory-confirmed influenza A in any given week and GBS hospitalization in the same week ([@bb1235]). A regression analysis for an expected delay between the influenza infection and GBS also showed a significant association for proven infections of influenza A and influenza B for individuals over the age of 35 years. However, they were not able to link the actual influenza virus infection to the individual with GBS.

The third epidemiologic study was a case-controlled study using data from the UK General Practice Research Database between 1991 and 2001 ([@bb1240]). The authors reported positive associations between GBS and infection with *Campylobacter*, Epstein--Barr virus, and influenza-like illnesses in the previous 2 months. There data provide evidence for patients with influenza-like illnesses having an 18-fold increased risk of GBS.

Unfortunately, not all epidemiologic studies have found an association between influenza infections and GBS. Two US studies failed to find any significant association between antecedent influenza and GBS ([@bb0635], [@bb0020]). A third Netherlands age- and sex-matched study of 154 GBS patients found significant serologic evidence of preceding infections of *C. jejuni*, cytomegalovirus, and Epstein--Barr viruses but only 3 patients (2%) had serologic evidence of a preceding infection with influenza A or B viruses ([@bb0575]).

If there is a true association between influenza and GBS, it must be weak and GBS does not occur during the acute influenza illness but within the month afterwards.

The association between influenza vaccination and GBS began in 1976 with the occurrence at Fort Dix, New Jersey, of human infections with a swine influenza A strain (Hsw1 N1 or A/NJ/1976/H1N1). Before then, no causal relationship between GBS and influenza vaccination had been epidemiologically documented and few cases after vaccination had been reported ([@bb0505]). In response to a perceived threat that the Hsw1N1 strain was similar to the 1918 pandemic strain, 40 million adults were vaccinated with a rapidly produced killed swine influenza vaccine. As the vaccination program proceeded, it became recognized that cases of GBS started appearing. Beginning about the second week after vaccination, a sharp rise in GBS cases occurred that peaked in the third week, followed by a fairly rapid decline that extended a total of 6 weeks ([@bb0700], [@bb1105], [@bb0820]). Since children under the age of 18 were not recommended for vaccination, few GBS cases developed in that age group. Compared to unvaccinated individuals who developed GBS, the increased relative risk rose to 12.7 per 1000 vaccinees for ages 25--44 years, 7.1 for ages 45--64, and 5.6 for ages over age 65 years ([@bb0700]). In all, there were 500 cases of GBS occurring among vaccinated persons, with 25 deaths. For all age groups, the rate for vaccinated cases was 7.3 and for unvaccinated cases 0.77, giving a ratio or relative risk of 9.5 to 1 or an increase of one case of GBS for every 100 000 adult vaccinations ([@bb0435]).

Beginning with the 1978 influenza vaccine program, active surveillance for GBS following vaccination has occurred. Most published reports have not found a statistically significant association between vaccination and GBS ([@bb0505], [@bb0610], [@bb0705]). In addition, a US Vaccine Adverse Event Reporting System (VAERS) supported by the CDC was established ([@bb0095]). VAERS is a voluntary reporting system for adverse events to all vaccines. VAERS and a similar UK reporting system have reported either no increased risk or a minimal increased risk of about one GBS case per million persons vaccinated associated with previous influenza vaccines ([@bb0100]). Regarding the 2009 H1N1 vaccine, as of April 2010, VAERS reported nearly 127 million doses of the 2009 vaccine being shipped to vaccination providers and having received only 136 GBS reports, which can be compared to a predicted 80--160 cases of GBS per week regardless of vaccination ([@bb0100]).

Currently, the CDC also conducts active GBS surveillance in 10 states in its Emerging Infections Program. As of March 31, 2010, individuals who received the 2009 influenza A vaccine had an estimated incidence of 1.92 cases of GBS per 100 000 person-years compared to an estimated incidence for non-vaccinated individuals of 1.21 GBS cases per 100 000 person-years ([@bb0105]). This significant excess risk relates to 0.8 cases per one million vaccinations.

At the moment, there is no satisfactory explanation why the 1976 swine influenza vaccine caused a much higher rate of associated GBS cases following vaccination compared to all subsequent influenza vaccine strains. One explanation given by the CDC is that the Fort Dix strain contained a "trigger element" ([@bb0700]). What the trigger element was is unclear despite considerable research. One possibility is that of molecular mimicry, with the vaccine triggering the production of antiganglioside antibodies in selected recipients which produced the GBS peripheral neuropathy ([@bb0910]).

Myalgia and myositis associated with influenza {#s0060}
==============================================

Patients developing influenza A or B infections commonly experience diffuse myalgias or muscle aches and pains early in the illness ([@bb0935]). The myalgias seldom interfere with muscle strength but can be associated with transient serum elevations of creatine kinase ([@bb0355]). The myalgias correlate with the severity of the influenza, last several days, and resolve along with the other symptoms during recovery. Muscle biopsies have not been done on these patients so the pathogenesis and pathology are unknown.

In a much smaller percentage of patients with influenza, the individual develops focal muscle aches and swelling later in the illness. The association of influenza and myositis was first described in 1957 with a series of 74 cases ([@bb0785]). Since then benign acute myositis has been reported in many epidemics of influenza A and B ([@bb0865], [@bb0380], [@bb0330], [@bb1075], [@bb0495]). In a series of 316 cases reviewed from the literature, the myositis usually developed in school-aged children (mean age of 8 years) with a 2:1 male predominance ([@bb0005]). About three-quarters of the infections were attributed to influenza B virus. The mean interval of myositis from onset of influenza symptoms was 3 days. The calf muscles were usually involved, with 69% being the only muscle group involved and 31% having calf and other muscles involved. The gastrocnemius is commonly tender to palpation (75%) and could have a mild swelling but the overlying skin was seldom warm to the touch or red. Walking is difficult and usually done with a limp. If both calves are involved, the child often refuses to walk. Serum creatine kinase is always elevated but rhabdomyolysis and renal failure occur in only 3%. The outcome is excellent, with symptoms of focal pain resolving in a median of 3 days. No studies have demonstrated that administration of anti-influenza drugs is effective in shortening the duration of the myopathy.

The muscle pathology of the involved muscles typically demonstrates segmental degeneration or rhabdomyolysis with or without accompanying inflammation ([@bb0850], [@bb0380], [@bb0135], [@bb0330], [@bb0060]). In a summary of 28 biopsy specimens, all showed degeneration and necrosis but six specimens showed no inflammation ([@bb0005]). The degeneration was quite focal and patchy. Frank hemorrhages did not develop. Attempts to isolate influenza virus from the muscle biopsy have varied. Often the isolation attempt was unsuccessful ([@bb0420], [@bb1100]) but influenza A or B virus has been isolated from several patients ([@bb0990], [@bb0380], [@bb0640], [@bb0645]). In addition, an immunohistochemical study from a muscle biopsy of a symptomatic patient demonstrated influenza viral antigen within myofibers often in a segmental pattern ([@bb0380]). Muscle fibers at the periphery of a bundle appeared to have more viral antigen than those that were central.

Experimental animal studies have also demonstrated that influenza virus can cause a focal infection of skeletal muscle. Influenza B/Lee virus inoculated into mouse thigh muscle caused a non-permissive or poorly permissive localized infection of muscle fibers ([@bb0195]). Serum creatine kinase levels became transiently elevated. Microscopic studies demonstrated segments of the muscle fiber with degeneration within the fiber and inflammation in the perimysium surrounding muscle fascicles. Immunohistochemistry and PCR assays confirmed the localized viral infection into specific nuclear domains of the muscle fiber consistent with the human biopsies. Virus was poorly isolated from the muscle and quantitative data suggested it was only residual virus from the inoculum.

*In vitro* studies of muscle cells from muscle biopsies infected with influenza virus have demonstrated viral replication with production of virions if the cultures were held at 36--37°C ([@bb0665], [@bb1120]). However, if the culture temperature was raised to a higher temperature, the infection was non-permissive ([@bb0165]).

In summary, viral myalgias are common with influenza but the pathology and pathogenesis for the diffuse muscle discomfort are unknown. Currently elevated serum cytokines are postulated to be the cause. The severity of the myalgia correlates with the severity of the influenza respiratory symptoms and with the titer of influenza virus shed from the nasopharynx ([@bb0445]). Children and occasional adults can develop a focal degeneration of mainly leg muscles that often demonstrates segmental involvement in muscle fibers. It is postulated that the respiratory infection results in a transient viremia ([@bb0915], [@bb1170]) that somehow localizes to calf muscles, producing mainly a non-permissive localized myopathy with limited inflammation. However, the occurrence of myositis did not correlate with the quantities of virus shed in the nasopharynx ([@bb0445]).

Myocarditis associated with influenza {#s0065}
=====================================

Cardiac dysfunction associated with influenza ranges from 0% to 10% depending on the methods used to detect myocardial involvement and occurs through direct effects of the virus on the myocardium or through exacerbation of existing cardiovascular disease ([@bb0805]). In general, the incidence of myocarditis is highest in hospitalized patients, in older adults, and in individuals with pre-existing pulmonary or cardiac disease. In spite of that, a series of 67 healthy Finnish conscripts hospitalized with influenza A were reported to have electrocardiac and echocardiologic evidence of myocarditis in 9% ([@bb0615]).

When acute myocarditis presents in a patient with influenza, the symptoms include chest pains or dyspnea. However, these same symptoms may also suggest the patient has congestive heart failure or pericardial effusion, making a clinical diagnosis more difficult. The cardiac symptoms usually develop within the first week of influenza onset. The electrocardiogram demonstrates non-specific tachycardia (also common in uncomplicated influenza) plus ST elevation associated with Q waves or occasionally left bundle branch block ([@bb1370]). Echocardiography usually shows left ventricular dysfunction with wall motion abnormalities and reduced ejection fractions ([@bb0315], [@bb1370]). Cardiac magnetic resonance imaging (MRI) has shown focal left ventricle edema on T2-weighted images, increased global relative enhancement on the T1-weighted gradient inversion recovery sequence, and epicardial late gadolinium enhancement ([@bb1370]).

Endomyocardial biopsies or myocardial examination at autopsy usually demonstrate multiple foci of active inflammation, focal edema, and varying degrees of myocyte degeneration or necrosis ([@bb0310], [@bb0065], [@bb0345]). Influenza virus occasionally is recovered from heart muscle or by PCR assays for influenza RNA of cardiac muscle but careful blood controls to rule out a viremic or nearby infected lung contamination are lacking ([@bb0600], [@bb0310], [@bb0065], [@bb0345]). Four children aged 3--9 years have been reported with myocarditis associated with 2009 influenza A ([@bb0305]). Three had fulminant myocarditis with full recovery but one died. This fatal case and one other had severe myocardial damage characterized by mononuclear infiltration. Reverse transcriptase-PCR (RT-PCR) assay for influenza viral RNA was positive in cardiac tissue.

Experimental mice were administered an aerosol of influenza A/PR/8/34 virus. Virus was isolated from cardiac tissue on days 3--7. Microscopic examination of the tissue demonstrated small necrotic foci with inflammatory cell infiltration spreading in the myocardium of days 3--7. The necrotic tissue was phagocytosed by macrophages and degenerating cardiocytes, macrophages, and lymphocytes were in close contact ([@bb0680]). Immunofluorescent studies demonstrated viral antigen in endothelial cells and cardiocytes until day 7. Cultured neonatal primary rat heart muscle infected with influenza virus demonstrated viral antigen in the nuclei and cytoplasm of the muscle cells but no virion production was observed, suggesting the infection was non-permissive ([@bb1190]).

Epidemics of influenza also are associated with an increased risk of autopsy-proven myocardial infarctions, which in one study rose 30% when compared to those in non-influenza winters ([@bb0795]). During periods of influenza, the risk of a cardiovascular death increases considerably in the elderly ([@bb0045], [@bb0015]). It is possible that myocarditis developing in a patient with impaired cardiac ejection fraction from pre-existing cardiac disease could lead to developing frank congestive heart failure from the influenza myocarditis.

In summary, influenza virus-associated myocarditis is more common than generally appreciated. When the myocarditis develops, other skeletal muscle pain may mask the chest pains ([@bb1315], [@bb1215]). In young patients, the myocarditis is usually non-fatal and reversible but the elderly may experience serious cardiac disease. Like the myositis considered above, it is unclear whether the pathogenesis of the myocarditis is secondary to direct virus infection of cardiac muscle fibers or to an indirect toxic effect such as elevated levels of serum cytokines.

Febrile seizures associated with influenza {#s0070}
==========================================

Febrile seizures are a common cause of childhood seizures. Febrile seizures are defined as a seizure in children aged 6 months to 5 years associated with fever but without evidence of intracranial infection or other definable cause ([@bb0120]). In one series of 73 children hospitalized for febrile seizures, a viral cause was thought to be responsible in 86% ([@bb0745]). Published series have determined that several common viruses are associated with febrile seizures and include influenza, adenovirus, parainfluenza, respiratory syncytial virus, and rotavirus ([@bb0125]). In series of hospital visits for febrile seizures, about 20% are associated with influenza ([@bb0120], [@bb0125]). The majority had a single uncomplicated partial or generalized seizure but 20--33% had more complex seizures that could be prolonged for more than 15 minutes, multiple seizures occurring within 24 hours, or postictal impairment of consciousness lasting for more than 30 minutes ([@bb0125]). Patients with febrile seizure should not have abnormalities on their EEG or neuroimaging and at discharge should be normal. In a series of 842 patients hospitalized with laboratory-confirmed influenza, 72 (0.9%) developed neurologic complications ([@bb0930]). Seizures were the reason for admission in 56 (58%) and febrile seizures in 27 of the 56 (48%). Whether influenza virus triggers a seizure simply by causing a childhood fever or whether there are other factors involved is unclear.

Encephalopathy with or without seizures associated with influenza {#s0075}
=================================================================

Encephalopathy with or without seizures appears to be the most common major neurologic association with influenza. The term encephalopathy implies a change in mental status lasting more than 24 hours that may be associated with seizures and occasionally focal neurologic signs but lacks evidence of inflammation of the brain or meninges. For epidemiologic purposes, the CDC defines influenza-related encephalopathy as patients who had altered mental status or personality changes lasting \> 24 hours and occurring within 5 days of an acute febrile respiratory illness that was proven subsequently to be laboratory-confirmed influenza ([@bb0930]).

The term encephalitis implies inflammation of the brain. Clinically the two conditions may be difficult to distinguish without a CSF examination, brain biopsy/autopsy, or good neuroimaging ([@bb0180]).

Influenza-associated encephalopathy has been described almost every year and was well recognized as far back as the 1918 influenza pandemic ([@bb0585]). The encephalopathy has been associated with influenza H1, H2, and H3 viral strains as well as influenza B strains ([@bb0965], [@bb1175], [@bb0755], [@bb0290]). It has been difficult to determine whether particular strains of influenza A or B have a higher incidence of encephalopathy.

Children with influenza-associated encephalopathy likely have been underdiagnosed as just very sick kids with the flu that were not hospitalized ([@bb1275]). As such, the true incidence is unknown. One study of 842 patients hospitalized with proven influenza from 2000 to 2004 reported that 10% developed neurologic symptoms and estimated the incidence as four cases per 100 000 person-years ([@bb0930]). Some series have reported that the risk of encephalopathy is higher in children with pre-existing neurologic problems. Another study evaluated children hospitalized with encephalitis or encephalopathy over an 11-year period ([@bb0025]). Of the 311 children identified, they found evidence of influenza viral infection in 5%.

Children under the age of 6 years have the highest risk of developing encephalopathy but it clearly can occur in adults ([@bb1175], [@bb0930]). Children and adults usually develop a non-productive cough, sore throat, and nasal congestion accompanied by a fever, headache, and myalgias ([@bb0810]). Diarrhea, nausea and vomiting may also occur in children. Beginning on the same day or within a few days, the individual becomes confused and may be delirious ([@bb1360]). In some individuals, the delirium can persist and patients develop hallucinations, inappropriate emotional outbursts of laughter or fear, mumbling and incoherent speech, or even psychosis ([@bb0500], [@bb0755], [@bb1275], [@bb1225], [@bb0400]). MRI scans in a few of these individuals, especially in Japan, who do not progress to coma show a reversible splenial lesion ([@bb1225]).

Generalized or complex partial seizures occur in about one-half of patients ([@bb0810]). Often the seizures are repetitive, may progress to status epilepticus, and are difficult to control with anticonvulsants ([@bb1195]). Within a few hours to a few days, the encephalopathy may worsen to where the patient becomes semicomatose or comatose. Some patients develop focal neurologic signs such as hemiparesis, aphasia, torticollis, and opisthotonus ([@bb0025]).

The large majority of individuals have a CSF that may be under increased opening pressure, lack a white blood cell (WBC) pleocytosis, and have normal CSF protein and glucose levels ([@bb1185], [@bb0025], [@bb0950], [@bb0290]). If the CSF contains many WBCs, the diagnosis is usually switched to encephalitis or to bacterial meningitis or aseptic meningitis ([@bb0930]). The blood seldom demonstrates characteristic abnormalities. The WBC may be normal or slightly elevated. Liver function studies usually are normal. However, occasional cases, especially from Japan, describe liver transaminase elevations and even arterial ammonia elevations that are very similar to RS ([@bb1195]). These cases are often described as Reye\'s-like, since in general these patients have not consumed aspirin or similar compounds.

The EEG may be normal, or demonstrate diffuse slowing, focal areas of slowing, epileptiform spikes, or seizures ([@bb1175], [@bb0810], [@bb0040]).

Neuroimaging by MRI is the most sensitive for detecting abnormalities. Many cases of encephalopathy have normal neuroimaging ([@bb0040]). Radiologists have divided the types of MRI images into several categories: normal, diffuse involvement with cerebral edema of the cerebral cortex, symmetric involvement of the thalami, basal ganglia and brainstem (ANE), and a postinfectious or acute disseminated encephalomyelitis category with multiple abnormal foci, mainly in the white matter ([@bb0655], [@bb1185]) ([Fig. 30.2](#f0010){ref-type="fig"} ). Occasionally the MRI may be normal early but develop abnormalities within a few days.Fig. 30.2A 12-year-old girl developed influenza encephalopathy. (**A**) Axial diffusion-weighted image magnetic resonance imaging with restricted diffusion in thalami bilaterally. (**B**) Accompanying apparent diffusion coefficient map.(Reproduced with permission from [@bb0790].)

Fortunately, individuals with only encephalopathy seldom die. The few autopsies of these patients have either been normal or demonstrate varying degrees of cerebral edema, usually without inflammation. The pathology of ANE is much different and is described below.

The majority of patients with only encephalopathy have a good prognosis but up to 30% may be discharged with neurologic sequelae that include hemiparesis, aphasia, cognitive loss, developmental delay, dysarthria, abnormal tremor or posturing, ataxia, and epilepsy ([@bb1175], [@bb0025]).

In addition to the typical encephalopathy associated with influenza, influenza has been associated with a variety of other neurologic signs or symptoms. They include vertigo lasting about a week ([@bb1335]), movement disorders such as choreoathetosis ([@bb1085]), and strokes ([@bb0930]).

Acute necrotizing encephalopathy associated with influenza {#s0080}
==========================================================

Beginning about 1994, some cases of encephalopathy associated with influenza have been much more severe, with very abnormal neuroimaging, coma, and \> 30% deaths ([@bb1270]). These patients are now described as having ANE. Although most of the cases have come from Japan, cases are now occasionally recognized around the world, including the United States ([@bb0790]). The majority of cases have been associated with influenza A (H3N2 or H1N1), but cases from influenza B virus are recognized ([@bb1095]).

Most cases are children under age 6 years with the neurologic symptoms beginning within 1--3 days of the onset of respiratory signs ([@bb0900], [@bb1270]). Adults can also develop ANE ([@bb0900]). Often the children become lethargic, experience single or multiple seizures, and lapse into a coma. The coma often is deep, requiring mechanical ventilation. The development of hypotension is not uncommon.

Individuals may have thrombocytopenia, elevated liver transaminases, and elevated ammonia levels ([@bb0900], [@bb1270]). The CSF usually has an elevated opening pressure when measured, lacks pleocytosis, has normal glucose, and only occasionally has an elevated protein ([@bb0365], [@bb0960]). The MRI may be normal but often demonstrates areas of T2-weighted enhancement in both basal ganglia, thalami, brainstem, cerebellar white matter, and cerebral white matter ([@bb0790]). Computed tomography shows hypointense lesions in the same regions ([@bb1095]). Depending on the Japanese series, deaths range from 30 to 40%, and 40% of survivors have neurologic sequelae with hemiparesis, paraplegia, choreoathetosis, parkinsonism, or dementia ([@bb0365]).

Autopsies have demonstrated diffuse cerebral edema with focal areas of necrosis in the same areas identified by MRI in life. These foci have necrotic cells, localized edema, congestion and hemorrhages, but have little inflammation in the lesions or meninges ([@bb1400], [@bb1095], [@bb1270], [@bb0660], [@bb0790]). One study reported histologic markers of apoptosis occurring in neurons and glia ([@bb1220], [@bb0920]). The cerebral blood vessels are not occluded by inflammatory cells or other debris but often had dilated Virchow--Robin spaces containing clear fluid ([@bb0560]). Many autopsy reports noted histologic evidence of vascular endothelial pathology with surrounding vasogenic edema ([@bb1195], [@bb0875]).

To date a wide variety of treatments have been tried, including anti-influenza drugs, steroids, plasmapheresis, intravenous immunoglobulin, hypothermia, anticonvulsants, and antibiotics, but none has been proven as being very helpful in preventing death or neurologic sequelae.

The precise incidence of neurologic complications during any year has been difficult to determine ([@bb0930]). However, since a large majority of individuals with influenza never seek medical attention or are hospitalized, the risk must be less than 1% of those infected. Most individuals with the encephalopathy do not have pre-existing neurologic illness or have a chronic immunosuppression, but clearly some do. In the past two decades, children less than 6 years appear to be at a greater risk than adults for developing ANE from the influenza A H3 and H1 strains. Uncomplicated encephalopathy occurred more often in children during the influenza A (H1N1) pandemic but that may have reflected that mainly children developed the H1N1 infection.

The pathogenesis of both encephalopathy and ANE associated with influenza are poorly understood. Two theories have been put forth but neither is proven.

There is increasing interest that the encephalopathy associated with the respiratory influenza infection may be due to several cytokines. However, production of proinflammatory cytokines is a normal defense mechanism in an influenza infection. A comprehensive study of 20 normal volunteers who were nasally infected with influenza A Texas/36/91 (H1N1) virus were serially followed with nasal and serum cytokine levels which correlated with symptoms and nasal viral titers ([@bb0470]). Influenza virus infection and replication in the respiratory tract directly injure the nasal and tracheobronchial epithelium. The resulting loss of respiratory epithelial cells is a major reason for several symptoms accompanying the infection, such as cough, depressed tracheobronchial clearance, and altered pulmonary function. Influenza virus induces a cascade of host immune responses leading to mucosal inflammation and the influx of polymorphonuclear cells, lymphocytes, and macrophages into the respiratory tract. It is this immune response that is responsible for resolution of the infection and possibly the clinical systemic symptoms. In the volunteer study, virus was recovered from nasal washes beginning on day 1, peaking on day 2 and persisting up to day 7. Peak influenza virus titers on day 2 were about 10^3.7^ 50% tissue culture infectious doses per mL. The patient temperature also peaked on day 2. Respiratory and systemic symptoms, such as fever, headache, and myalgias, also peaked on day 2 and persisted to about day 6. Two cytokines, IL-6 and IFN-α, peaked in the nasal washes and serum on day 2 but serum TNF-α peaked on day 4. Serum IL-6 levels were about fourfold above normal. Plasma and serum IL-6 levels nicely correlated with total systemic symptoms on days 2--4. Considerable evidence finds that the cytokines studied were produced locally in the respiratory tract by both infected respiratory epithelial cells and immune invading cells. Another study reported similar findings ([@bb0595]). Thus, several cytokines appear responsible for both clearance of the respiratory infection and production of common influenza systemic symptoms.

Recent studies of serum and cytokine levels from patients with influenza who developed an encephalopathy have suggested that very elevated cytokine levels may be in part responsible for the encephalopathy. Studies of patients with encephalopathy have reported very elevated serum and/or CSF elevated levels of IL-1α, IL-6, IL-8, IL-10, IL-15, and TNF-α, and soluble TNF receptor ([@bb0545], [@bb1265]). Furthermore, when patients were divided into categories ranging from simple respiratory illness, to febrile seizures, and encephalopathy, those with the encephalopathy generally had the highest serum levels ([@bb0535], [@bb0550], [@bb0630], [@bb0570], [@bb0370]). Individuals with ANE often, but not always, had extremely elevated serum and CSF levels of IL-6 ([@bb1405], [@bb0540], [@bb0950]). Thus, there was a correlation between very elevated serum cytokine levels and poor outcome from death or neurologic sequelae. The viral pneumonia complicating the pandemic 2009 H1N1 infection is a primary source of elevated cytokine production ([@bb1265]).

Complicating the analysis is that many patients with ANE also had a viral pneumonia that could have contributed to the elevated cytokine levels ([@bb1265]).

In addition, very elevated CSF cytokine levels have been reported in other illnesses, including other viral encephalitis ([@bb0555]). Finally, the mechanism by which elevated serum or CSF cytokine levels actually cause the cerebral edema or focal areas of necrosis in selected areas of the brain is unclear. However, it has been postulated that several cytokines, including IL-6, TNF- α, and IL-1, can induce disruption of the blood--brain barrier in animals and *in vitro* ([@bb1090], [@bb0255]).

An alternative theory is that influenza virus directly plays a role in the encephalopathy. This hypothesis is complicated as there is almost no evidence that influenza virus fully replicates in the brain, causing encephalitis. Isolation of influenza virus from brain lesions or CSF is unusual ([@bb0350]) and evidence of influenza replications in organs outside the respiratory tract is uncommon. The histopathology of the encephalitis does not show inflammation, as would be expected from most forms of encephalitis.

There is some evidence supporting some direct role of influenza virus in the encephalopathy. The hypothesis would be that a non-permissive or abortive influenza virus infection of the brain or cerebral blood vessels is the cause. The influenza virus is normal but the cell that the virus infects is non-permissive for a full cycle of replication. A non-permissive infection of many non-respiratory cells in humans and animals has been demonstrated. In these cells the virus starts the replication cycle in the cell, causes dysfunction of the cell, but fails to produce progeny virions that can produce additional cycles of replication or be isolated from the cells.

Influenza virus can cause a viremia in humans, particularly early in the infection and before clinical symptoms ([@bb0915], [@bb1170], [@bb0650], [@bb0725], [@bb1395]). The incidence of the viremia appears low based on blood PCR assays of patients with influenza respiratory symptoms ([@bb0885]) and blood isolation attempts in larger series of patients ([@bb0650]).

The non-permissive theory argues that the initial respiratory influenza viral infection produces an early viremia that secondarily infects brain endothelial cells (producing cerebral edema with headache or encephalopathy), myocytes (producing myalgia or myositis), myocardium (producing myocardopathy), and hepatocytes (producing liver enzyme dysfunction and RS).

In a few autopsies, influenza viral antigen has been detected in brain ependymal cells ([@bb0350]), in Purkinje cells and some pontine nuclei ([@bb1220]), and within capillary vessel walls of the basal ganglia ([@bb0560]). Detection of influenza RNA by RT-PCR assays has been reported to be positive in both brain tissue and CSF ([@bb0360], [@bb0900], [@bb1175], [@bb1270], [@bb0290]). However, other studies using PCR assays have been negative in single case reports or reported as positive in less than half of attempts in their series ([@bb0365], [@bb1130], [@bb0900], [@bb1175], [@bb1270], [@bb0790]).

Support for the non-permissive theory exists in experimental animals. Following intranasal inoculation, intravenous inoculation, or direct muscle injection, human influenza virus in mice or hamsters produces a non-permissive viral infection in cerebral endothelial cells causing cerebral edema, in muscle myofibrils causing myositis, in myocardium causing myocarditis, and in hepatocytes causing a fatty steatosis similar to that seen in RS ([@bb0175], [@bb0220]). The non-permissive viral infection transiently produces viral nucleic acid and viral antigens for 1--3 days but produces very little, if any, infectious virions and results in little tissue inflammation.

Neurologic syndromes associated with avian influenza h5n1 {#s0085}
=========================================================

Avian influenza is different from seasonal and pandemic strains in three respects.

First, although less than 500 human cases of avian H5N1 influenza have been recorded, the high mortality rate of approximately 60% ([@bb1390]) has raised the fear that a future highly pathogenic H5N1 strain acquiring human transmissibility will produce the greatest worldwide pandemic. Second, avian influenza strains of subtype H5 were never recognized in humans until 1997 during a small outbreak in Hong Kong. Evolution of these strains through mutation resulted in greater viral replication efficiency in mammalian cells ([@bb1285]). Subsequently explosive spread of avian influenza began in 2004 and within 2 years had spread throughout Asia with extension to Europe and Africa. Multiple clades of H5N1 viruses have evolved over the last dozen years ([@bb0110]), complicating the prediction of suitable vaccines. Although the immediate source of infection is usually not identified, contact with domestic poultry has been a constant association with human infection and epizootics of avian flu in domestic fowl have led to the destruction of millions of birds. Low pathogenic influenza viruses are enzootic in feral water fowl but introduction into domestic poultry appears to accelerate adaptation, virulence, and high levels of aerosol transmission among crowded flocks ([@bb0715]). H7 and H9 subtypes have also infected humans but the disease is in general mild and not thought to represent a pandemic threat.

Population-based surveys of farmers, merchants, and cooks in close contact with poultry production and preparation find a low seroprevalence of antibody to the H5 HA. Human-to-human transmission of avian influenza is rare ([@bb1355]), so it appears that very close contact with infected fowl is required for infection. Underlying disease does not predispose to death, but children and adolescents are overrepresented among death statistics ([@bb0605]). Although most infecting strains are resistant to amantadine but sensitive to oseltamivir, treatment with NA inhibitors or ribavirin does not seem to alter the disease course.

The third reason that avian influenza is unique among the influenza viruses is its multiorgan dissemination of infection seen in both animal models and humans.

The sialic acid-decorated glycolipids and glycoproteins that serve as receptors for the HA protein are ubiquitous on the surface of most avian and mammalian cells. In most avian species influenza is primarily an enteric infection, with highest titer of virus found in the cloaca. Intestinal infection following intranasal inoculation in the ferret has been documented and results in diarrhea. CNS infection is well described in many bird species, with infection of neurons and microglial cells documented ([@bb1310]). Mouse microglia and astrocytes bear both the α-2,3-gal and α-2,6-gal receptors and are productively infected *in vitro* by both human and avian viruses ([@bb1355]). Extrapulmonary dissemination is characteristic of H5N1 infection in mice ([@bb0390]). Note that H5N1 viruses display a predilection for binding to the α-2,3-galactose-linked sialic acid receptors found predominantly in human lower respiratory tract mucosal epithelial cells ([@bb1140]). Thus it is recommended that in early infection diagnosis is better achieved from specimens taken from the lower respiratory tract ([@bb1415]).

The anatomic routes of entry from the initial mucosal infection to non-mucosal tissues are not yet clear. Viremia has been documented but appears to be rare. In a murine model of an H5N3 virus inoculated intranasally, viral antigen was detected initially in vagal and trigeminal ganglia but not in the blood ([@bb1135]). In the mouse model several routes of entry of the virus into the brain have been suggested. Intranasal inoculation of highly pathogenic H5N1 virus appeared to enter via the mesenteric and myenteric plexi of the enteric nervous system prior to appearing in the brainstem nuclei ([@bb0580]). Inoculation with a dose lethal to half the mice resulted in large weight loss, ataxia, tremor, and bradykinesia in all the animals. This study also found that, among survivors examined 90 days after infection, neuronal loss, abnormal protein aggregations, and microglial activation were prominent, all hallmarks of the neurodegenerative diseases, including Parkinson\'s and Alzheimer\'s diseases.

In ferrets inoculated intranasally with the highly pathogenic HPAI H5N1 virus, high titers of virus appeared in the periglomerular and mitral cells of the olfactory bulb within 24 hours of inoculation, with later spread to neurons and microglial cells in the brainstem and all other lobes. CNS lesions were focal non-suppurative collections of karyorrhectic cells and influenza antigen concentrated in cellular nuclei and surrounding debris, with scattered regions of purulent meningitis. This sequence suggests that entry was from the sensory epithelial cells in the dorsal turbinates through the cribiform plate to neuronal tracts throughout the CNS (F. Koster, unpublished data).

Ferrets infected with HPAI in the respiratory tract exhibit replication to high titers in multiple systemic organs, including the spleen, liver, bone marrow, intestine, and brain ([@bb1420], [@bb0800]). The majority of ferrets exhibit severe neurologic signs, including hemiparesis, convulsions, torticollis, and spasticity prior to death ([@bb1070]). High levels of cytokine secretion are found in mouse ([@bb0770], [@bb1210]) and ferret ([@bb0090]) models. However, in view of the extensive regions of necrosis in all lobes of the ferret brain in sites of replicating virus, it is difficult to escape the conclusion that the meningoencephalitis is due primarily to the cytolytic viral replication.

Human neurologic sequelae of H5N1 HPAI infections are clearly different from that in the ferret model. The few postmortem studies have not yet been able to elucidate thoroughly the pathogenesis of this severe disease, but available data have been summarized in detail ([@bb0385], [@bb0675]). Most deaths have occurred in China, Vietnam, and Indonesia and are usually due to acute respiratory death syndrome ([@bb0625]) and well-described cases do not include neurologic symptoms and signs ([@bb0485]). In a study of a 6-year-old boy who died of acute respiratory distress syndrome on the 17th day of illness, viral RNA and antigen were not detected in the brain or trachea but were detected in spleen, large and small intestine, and lung tissue, where it was restricted to the type II alveolar pneumocyte ([@bb1290]). Positive-strand viral RNA was restricted to the lung and intestine, indicating that viral replication was occurring in only these two organs. Viral dissemination was found in another patient by immunohistochemical demonstration of viral antigen in bone marrow, glial cells, and neurons in the brain and in lymphocytes, but viral replication by culture was found only in the lung and upper respiratory tract ([@bb1410]). In a careful study of two adults and a fetus, viral antigen and viral RNA by *in situ* hybridization with sense and antisense probes was detected in type II alveolar epithelial cells, ciliated and non-ciliated tracheal cells, T cells of the lymph node, neurons in the brain, and cytotrophoblasts of the placenta ([@bb0425]). This widespread dissemination of replicating virus was confirmed by strand-specific RT-PCR, real-time RT-PCR, and nucleic acid sequence-based amplification H5 detection assays, yet despite the evidence for viral replication in the brain, there was no histopathologic evidence for inflammation in the brain.

Viral replication may not be specifically pathogenic in the brain. The alternative explanation is indicated by the numerous studies finding hyperinduction of cytokines and chemokines associated with multiorgan failure and death ([@bb0115], [@bb1000], [@bb0225], [@bb0230], [@bb1290], [@bb1265]). In 18 individuals with H5N1 infection the low blood T lymphocyte counts and high levels of proinflammatory cytokines and chemokines were correlated with high pharyngeal viral loads and detection of viral RNA in blood and rectum, particularly in fatal cases ([@bb0230]). Although suppression of the host inflammatory response may confer some therapeutic benefit, anecdotal experience with corticosteroids did not improve the clinical outcome in H5N1 infection ([@bb0955]). In a murine model study anti-TNF-α antibodies reduced illness severity ([@bb0520]), suggesting more exploration of this strategy.

Conclusion and future of influenza infections of humans {#s0090}
=======================================================

Human and animal influenza viral infections have been present for centuries. Influenza virus has the ability to mutate frequently to a new strain as well as reassort some of its eight RNA segments when two strains are co-infected in the same cell. The result is that every year slightly different strains appear in the population, allowing for it to have a widespread circulation. Every decade or so a major change occurs in the HA or NA outer protein coat that enables the virus to become virulent to most of the world\'s population, setting forth a pandemic. The recent pandemic 2009 H1N1 means the prediction of future pandemics remains uncertain ([@bb1260]).

As the human population becomes denser and the citizens of many countries live in close proximity to either pigs or birds, the risk of a virulent avian influenza strain mutating to enable both infection of humans and spread between humans is very real. Currently uncertain is whether the sporadic spread of avian H5N1 infection, which is very virulent in humans, will evolve to a highly pathogenic strain capable of human-to-human transmission. If so, we could face an influenza pandemic that carries a mortality rate as high as or higher than the 1918 influenza pandemic.

To date, the major approach of managing influenza infections is via prevention through yearly vaccination programs. While this is highly effective in either preventing or lessening the severity of the influenza, production of a new vaccine requires months, is expensive, and is hard to distribute quickly around the world, let alone in developed countries. However, the incubation period of influenza is only a few days and in the world of airplane travel could spread around the world in weeks before any vaccine could be developed. On the positive side, there are several new approaches in development toward producing influenza vaccines rapidly ([@bb0690]).

At present, we lack highly effective anti-influenza drugs. With respect to the neurologic complications of the latest influenza A H1N1 pandemic, there is no strong evidence that any of the existing anti-influenza drugs, including oseltamivir, were beneficial in treating the encephalopathy. There is a need to develop more potent anti-influenza medications that have application for a wide range of influenza strains and cross the blood--brain barrier.

Finally, we need a better understanding of how influenza virus causes the occasional neurologic complications. At present, evidence suggests that there may be several pathogenic mechanisms involved. If elevated blood or CSF cytokine levels are proven to be the cause, better agents to block the key cytokines are needed.
